Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...
CGEN stock is up on an exclusive licensing deal Compugen (NASDAQ:CGEN) stock is rocketing higher on Tuesday after announcing an exclusive licensing agreement…
Gilead Sciences Inc. announced an agreement with Compugen Ltd. to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503...
Shares are halted for volatility but rise to highest levels since mid-2022 on resumed trading.
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.